Vir Biotechnology (NASDAQ:VIR) Given New $28.00 Price Target at Barclays
Vir Biotechnology (NASDAQ:VIR – Free Report) had its price objective upped by Barclays from $27.00 to $28.00 in a report issued on Friday morning, Benzinga reports. They currently have an overweight rating on the stock. Several other equities analysts have also recently commented on the stock. HC Wainwright reissued a buy rating and set a […]
More Stories
CSX Co. (NASDAQ:CSX) Given Average Rating of “Moderate Buy” by Analysts
CSX Co. (NASDAQ:CSX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fifteen analysts...
UN’s Guterres urges global solutions as uncertain world edges toward a ‘powder keg’
The world is locked in a “purgatory of polarity” with a growing number of governments and others feeling entitled to...
Arena REIT (ARF) to Issue Interim Dividend of $0.05 on November 6th
Arena REIT (ASX:ARF – Get Free Report) declared a interim dividend on Tuesday, September 24th, MarketIndexAU reports. Investors of record...
Sudan crisis must not be forgotten by world leaders, says UN food agency
Ongoing heavy fighting in Sudan has continued to kill and uproot the country’s people who global leaders should remember as...
US Plans to Bring Attempted Assassination Charge Against Ryan Routh
By Jack Phillips and T.J. Muscaro WEST PALM BEACH, Fla.—Federal prosecutors are looking to bring a charge of attempted assassination...
China, Iran, Russia Using AI to Influence US Elections, Intelligence Community Warns
By Tom Ozimek Foreign powers are increasingly using artificial intelligence (AI) to influence how Americans vote, according to a new...